Progress in the prevention of type 2 diabetes;Fortschritte in der prävention des typ-2-diabetes

Wiener Klinische Wochenschrift

Volumn 115, Issue 21-22, 2003, Pages 745-757

  Schernthaner, Guntram ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Acarbose; ACE inhibitors; DPP; Metformin; Prevention; STOP NIDDM; Type 2 diabetes

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; METFORMIN; PLACEBO; RAMIPRIL; TROGLITAZONE;

DIET; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EXERCISE; GLUCOSE INTOLERANCE; HEALTH PROGRAM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK REDUCTION; WEIGHT REDUCTION;

EID: 0346504112     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03040499     Document Type: Review

References (70)

1. Economic consequences of diabetes mellitus in the U.S. in 1997 (1998) American Diabetes Association. Diabetes Care 21: 296-309
2. Knowler WC, Sartor G, Melander A, Schersten B (1997) Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 40: 680-686
3. Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2001) Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24: 447-453
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
5. Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15: 815-819
6. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al (2001) Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24: 1936-1940
7. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25: 829-834
8. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46: 182-189
9. Likitmaskul S, Kiattisathavee P, Chaichanwatanakul K, Punnakanta L, Angsusingha K, Tuchinda C (2003) Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity. J Pediatr Endocrinol Metab 16: 71-77
10. Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708-723
11. Heine RJ, Dekker JM (2002) Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002 45: 461-475
12. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287: 356-359
13. Eriksson KF, Lindgarde F (1998) No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 41: 1010-1016
14. Joslin E (1921) The prevention of diabetes mellitus. JAMA 76: 79-84
15. WHO Study Group (1994) Primary prevention of diabetes mellitus - Technical Report Series No 844. Geneva Report No 844
16. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345: 790-797
17. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G (2003) Impact of weight loss on inflammatory proteins and their association to the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23: 1042-1047
18. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, Roka R, Minar E, Schernthaner G (2003) Weight loss reduces tissue factor in morbidly obese patients. Obesity Research 11: 950-956
19. Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, Rosner B, Hennekens CH, Speizer FE (1991) Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 338: 774-778
20. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr (1991) Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 325: 147-152
21. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544
22. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al (2001) Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350
23. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
24. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al (2002) Acarbose for prevention of type-2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072-2077
25. The Diabetes Prevention Program Research Group (2003) Prevention of type 2 diabetes with troglitazone in the diabetes prevention program (DPP). Diabetes 52 [Suppl 1]: A 58
26. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trial Research Group (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486-494
27. Hanefeld M, Petzinna D, Catagay M (2003) Acarbose treatment reduces the incidence of cardiovascular complications in patients with type-2 diabetes: a metaanalysis. Eur Heart J (in press)
28. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51: 2796-2803
29. Eccles M, Hawthorne G, Whitty P, Steen N, Vanoli A, Grimshaw J, Wood L (2002) A randomised controlled trial of a patient based Diabetes recall and Management system: the DREAM trial: a study protocol. BMC Health Serv Res 2: 5
30. Sjöström L, Torgerson JS, Hauptman J, Boldrin M (2002) XENDOS (XENical in the Prevention of Diabetes in Obese Subjects). 9th International Congress of Obesity, Sao Paulo
31. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342: 905-912
32. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611-616
33. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B (2001) Ramipril and the development of diabetes. JAMA 286: 1882-1885
34. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, De Faire U, Fyhrquist F, Julius ST, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn ST (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004-1010
35. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 288: 2981-2997
36. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C, Kuenburg E, Schernthaner G (1991) Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension 17: 15-21
37. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM (2003) Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 41: 431-436
38. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H (2003) Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Br Med J 326: 681
39. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357-362
40. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158
41. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016
42. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E (2003) Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138: 1-9
43. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333
44. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI (2002) Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288: 2432-2440
45. Lokkegaard E, Pedersen AT, Heitmann BL, Jovanovic Z, Keiding N, Hundrup YA, Obel EB, Ottesen B (2003) Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study. BMJ 326: 426
46. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV (2003) Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation 107: 43-48
47. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427
48. Tsumura K, Hayashi T, Suematsu C, Endo G, Fujii S, Okada K (1999) Daily alcohol consumption and the risk of type 2 diabetes in Japanese men: the Osaka Health Survey. Diabetes Care 22: 1432-1437
49. Conigrave KM, Hu BF, Camargo CA Jr, Stampfer MJ, Willett WC, Rimm EB (2001) A prospective study of drinking patterns in relation to risk of type 2 diabetes among men. Diabetes 50: 2390-2395
50. Valmadrid CT, Klein R, Moss SE, Klein BE, Cruickshanks KJ (1999) Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA 282: 239-246
51. Ajani UA, Gaziano JM, Lotufo PA, Liu S, Hennekens CH, Buring JE, Manson JE (2000) Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 102: 500-505
52. Solomon CG, Hu FB, Stampfer MJ, Colditz GA, Speizer FE, Rimm EB, Willett WC, Manson JE (2000) Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. Circulation 102: 494-499
53. de Vegt F, Dekker JM, Groeneveld WJ, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ (2002) Moderate alcohol consumption is associated with lower risk for incident diabetes and mortality: the Hoom Study. Diabetes Res Clin Pract 57: 53-60
54. Bell RA, Mayer-Davis EJ, Martin MA, D'Agostino RB Jr, Haffner SM (2000) Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study. Diabetes Care 23: 1630-1636
55. Bouchardat A (1875) De la glycosurie ou diabete sucre. Germer-Bailliere, Paris
56. Himsworth H (1935) Diet and the incidence of diabetes mellitus. Clin Sci Mol Med 2: 117-148
57. Westlund K (1966) Incidence of diabetes mellitus in Oslo, Norway, 1925-1954. Br J Prev Soc Medical 20: 105
58. Stanner SA, Bulmer K, Andres C, Lantseva OE, Borodina V, Poteen VV, Yudkin JS (1997) Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study. BMJ 315: 1342-1348
59. Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288: 1723-1727
60. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN (2003) Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 138: 215-229
61. Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A (2003) Screening for Type 2 diabetes - should it be now? Diabet Med 20: 175-181
62. American Diabetes Association (2003) The prevention or delay of type 2 diabetes. Diabetes Care 26 [Suppl 1]: 62-69
63. Zimmet P, Shaw J, Alberti KG (2003) Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 20: 693-702
64. Gary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL (2003) Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ 29: 488-501
65. Wenying Y, Lixiang L, Jinwu Q, Zhiqing Y, Haicheng P, Guofeng H (2001) The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 17: 131-136
66. Fujimoto WY, Diabetes Prevention Program Research Group (2000) Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care 23 [Suppl 2]: B11-13
67. Palmer AJ, Roze S, Comte S, Cabrieres L (2002) Cost-effectiveness of intensive lifestyle changes or metformin overnight, glucose intolerant patient: modelling the long-term implications of the diabetes prevention program in the French, German and UK settings. Diabetologia 45: 938
68. Swinburn BA, Metcalf PA, Ley SJ (2001) Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 24: 619-624
69. Wing RR, Goldstein MG, Acton KJ, Birch LL, Jakicic JM, Sallis JF Jr, Smith-West D, Jeffery RW, Surwit RS (2001) Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 24: 117-123
70. Diabetes Prevention Program Research Group (2003) Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26: 977-980